Top ▲

Vitiligo

GtoPdb Disease Summaries

This section gives an overview of the disease, and where available shows the following:

  • Synonyms: Shows known synonyms for the disease.
  • Description: Gives a basic description/definition of the disease.
  • Database Link: External links to the same disease at the Disease Ontology, OMIM or Orphanet sites.
  • Immunopharmacology comments: General comments about the target's role in immunopharmacology, provided by GtoImmuPdb curators.
  • Associated with: Counts are displayed for the total targets the disease is associated with in GtoPdb. The counts of targets and ligands of immunological relevance associated to the disease are also shown.

More information can be found in the help pages.

✖
Disease ID:1251
Name:Vitiligo
Associated with:0 target
1 immuno-relevant ligand
Description
Vitiligo is an autoimmune disease, in which immune-mediated destruction of melanoctyes causes depigmentation of the skin.
Database Links
Disease Ontology: DOID:12306
OMIM: 193200

Targets

GtoPdb Disease Summaries - Targets

Click on the target name to link to its detailed view page

Where available, information is display on the role of the target in the disease; drugs which target the disease and their therapeutic use and side-effects.

If there is mutation data curated in GtoPdb this is indicated, with a link back to the appropriate section on the target detailed view page

Immuno ligand interactions - If available, a table of immuno-relevant ligands is shown. These ligands have been curated as having an association to the disease and possess interaction data with the target in GtoPdb. The approval status of the ligand is shown, along with curator comments and an indication of whether the target is considered the primary target of the ligand.

More information can be found in the help pages.

✖
Key to terms and symbols

No target related data available for Vitiligo

Ligands

GtoPdb Disease Summaries - Ligands

Click ligand name to view ligand summary page

  • Approved: If the ligand is an approved drug this is indicated, along with approval bodies.
  • Immuno: Immuno icon indicates the ligand is immuno-relevant

Click the arrow in the final column to expand comments

  • Immuno Disease Comments: Curatorial comments specifically added as part of GtoImmuPdb. They give more information on the association between the ligand and disease in the context of immunopharmacology.
  • Clinical Use: General clinical comments relating to the ligand and may not necessarily be specific to the disease in question. With hyperlink to more details on the ligand summary pages.
  • Bioactivty Comments: Curatorial comments specifically about the compounds biological activity - with hyperlink to more details on the ligand summary pages.

More information can be found in the help pages.

✖
Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
programmed cell death 1 ligand 1 6
Immuno Disease Comments: PD-L1 fusion protein treatment has been shown to increase Treg abundance and reduce/reverse depigmentation development in Pmel-1 vitiligo mice.
Clinical Use: PD-L1 is an important immunopharmacological drug discovery target, as many types of cancer cells express this ligand [2-3,7] as a means of evading immune detection and destruction by T-cell-mediated responses. Three monoclonal antibodies directed against PD-L1 are approved cancer therapeutics. Additional reading: [5] and [4]. | View clinical data
Bioactivity Comments: Combined anti-PD-L1+anti-CTLA-4 therapy has shown benefits over anti-PD-L1 monotherapy in head and neck cancer. Compared to monotherapy, the combination approach is reported to induce more efficient CD4+ T cell trafficking from lymph nodes to tumours and to promote expansion toward T helper 1 phenotype [1]. | View biological activity

References

Show »

1. Dietl A, Ralser A, Pelka K. (2024) Dual checkpoint T(h1)eamwork makes the anti-cancer dream work. Immunity, 57 (3): 406-408. [PMID:38479356]

2. Greaves P, Gribben JG. (2013) The role of B7 family molecules in hematologic malignancy. Blood, 121 (5): 734-44. [PMID:23223433]

3. Janakiram M, Abadi YM, Sparano JA, Zang X. (2012) T cell coinhibition and immunotherapy in human breast cancer. Discov Med, 14 (77): 229-36. [PMID:23114578]

4. Johnson DB, Rioth MJ, Horn L. (2014) Immune checkpoint inhibitors in NSCLC. Curr Treat Options Oncol, 15 (4): 658-69. [PMID:25096781]

5. Lu J, Lee-Gabel L, Nadeau MC, Ferencz TM, Soefje SA. (2015) Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy. J Oncol Pharm Pract, 21 (6): 451-67. [PMID:24917416]

6. Miao X, Xu R, Fan B, Chen J, Li X, Mao W, Hua S, Li B. (2018) PD-L1 reverses depigmentation in Pmel-1 vitiligo mice by increasing the abundance of Tregs in the skin. Sci Rep, 8 (1): 1605. [PMID:29371688]

7. Tang PA, Heng DY. (2013) Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer. Curr Oncol Rep, 15 (2): 98-104. [PMID:23263823]